SG33, a vaccine strain of myxoma virus with oncolytic potential, exploits macropinocytosis and clathrin-mediated endocytosis for entry into pancreatic cancer cells.
Nikolaos Kontopoulos, Noémie Delenclos, Lætitia Ligat, Sokunthea Top, Franck Gallardo, Stéphane Bertagnoli, Nelson Dusetti, Louis Buscail, Pierre Cordelier
This study identifies the entry mechanisms of SG33, an oncolytic myxoma virus, into pancreatic cancer cells, showing it uses macropinocytosis and clathrin-mediated endocytosis.
Human Gene Therapy · Apr 10, 2026Peer-reviewedCancer Biology